Literature DB >> 18166841

"Salvage" surgery for primary mediastinal malignancies: is it worthwhile?

Francesco Petrella1, Francesco Leo, Giulia Veronesi, Piergiorgio Solli, Alessandro Borri, Domenico Galetta, Roberto Gasparri, Rosalba Lembo, Davide Radice, Paolo Scanagatta, Lorenzo Spaggiari.   

Abstract

INTRODUCTION: Indications and results of salvage surgery in mediastinal tumors are still unclear. This study analyzes a single-center experience to assess its mortality, morbidity, and long-term results.
METHODS: Mediastinal salvage surgery (MSS) was defined as surgical resection of persistent or recurrent primary mediastinal tumors after previous local treatments with curative intent or exclusive chemotherapy in case of bulky tumors. Clinical data of patients undergoing MSS between 1998 and 2005 were analyzed. Overall and disease-specific long-term survival was calculated.
RESULTS: Twenty-one patients (15 men and 6 women, mean age 41 years) underwent MSS. Eleven patients suffered from thymic tumors (eight thymomas, three thymic carcinoma) whereas 10 patients suffered from nonthymic tumors (one lung adenocarcinoma + thymoma, two mediastinal monophasic sinovial sarcoma, one mediastinal neuroendocrine tumor, one mediastinal teratoblastoma, one mediastinal disgerminoma, one Hodgkin's lymphoma, one mediastinal atypic carcinoid, two medullary thyroid carcinoma). MSS required extended vascular resection in 10 cases and cardiopulmonary bypass in one case. Median operation time was 215 minutes (range 140-720). One postoperative death and four major complications were recorded (overall mortality 4.7%, morbidity 19.0%). With a median follow-up of 30.6 months, overall 1-, 3-, and 5-year Kaplan-Meier survival was 89.7, 71.2, and 56.6%, respectively. Thymic neoplasms had a better prognosis (1-, 3-, and 5-year survival was 100, 87.5, 87.5%, respectively) when compared with others (1-, 3-, and 5-year survival was 77.8, 53.3, 26.7%, respectively--logrank p = 0.0128).
CONCLUSIONS: MSS can offer a chance of curative treatment in selected patients with an acceptable morbidity and mortality. Thymic tumors obtain the best results in term of long-term survival.

Entities:  

Mesh:

Year:  2008        PMID: 18166841     DOI: 10.1097/JTO.0b013e31815e6d54

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

Review 1.  Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.

Authors:  Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-03-04       Impact factor: 1.520

2.  Postoperative radiotherapy for residual tumor of primary mediastinal carcinoid teratoma.

Authors:  Lingli Tu; Lan Sun; Yu Zhou; Youling Gong; Jianxin Xue; Jun Gao; You Lu; Yongsheng Wang
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

3.  Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

Authors:  Weian Song; Shouyin Di; Junqiang Liu; Boshi Fan; Jiahua Zhao; Shaohua Zhou; Siyu Chen; Hai Dong; Caiying Yue; Taiqian Gong
Journal:  Thorac Cancer       Date:  2020-02-28       Impact factor: 3.500

4.  Salvage surgery using simultaneous clamshell thoracotomy with median sternotomy for mediastinal growing teratoma syndrome.

Authors:  Chieh-Ni Kao; Shah-Hwa Chou; Chien-Lin Huang; Chih-Hung Lin; Hung-Hsing Chiang; Jui-Ying Lee; Hsien-Pin Li; Po-Chih Chang; Yu-Wei Liu
Journal:  Thorac Cancer       Date:  2020-01-11       Impact factor: 3.500

5.  Prognostic Value of the Hemoglobin/Red Cell Distribution Width Ratio in Resected Lung Adenocarcinoma.

Authors:  Francesco Petrella; Monica Casiraghi; Davide Radice; Andrea Cara; Gabriele Maffeis; Elena Prisciandaro; Stefania Rizzo; Lorenzo Spaggiari
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

6.  Salvage surgery for stage IVa thymic carcinoma combined with aortic arch resection - case report.

Authors:  Hiroyuki Yamato; Soichiro Funaki; Kazuo Shimamura; Keiwa Kin; Toru Kuratani; Yoshiki Sawa; Yasushi Shintani
Journal:  J Cardiothorac Surg       Date:  2020-10-07       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.